After the closing bell Thursday, plenty more big name companies reported their quarterly earnings. Aside from Amazon.com's (AMZN) blowout quarter that trounced estimates on the top and bottom lines, we also heard from biotech majors Amgen (AMGN) and Gilead (GILD). Following a disappointment in its Q4 2016 earnings report, Amazon has returned to its winning -- and opulent! -- ways: a 75 percent positive earnings surprise and an extra billion in revenues came in for the first three months of the year: Amazon Crushes Q1 Earnings, Stock Soars 11% Not only that, but going a little bit more in-depth, Amazon's web services gained a full 64 percent year-over-year: Amazon Q1 Earnings In-Depth: Web Services Up 64% And in case you now think you know everything there is to know about Amazon stock, make sure you're fully versed on Amazon as a company with several different entities: The Complete Guide to Everything Owned by Amazon As for Amgen, the biotechnology swept Q1 earnings in the top 3 major categories: a beat on earnings, a beat on sales and a raise to overall 2016 guidance: Amgen Beats Q1 Earnings Estimates, Raises 2016 Outlook Gilead, however, did not manage to perform as well in its Q1. Shares fell in late-day trading following the company's disappointing earnings release: Gilead Sciences Stock Slumps on Q1 Earnings, Revenue Miss Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AMAZON.COM INC (AMZN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research